Tatva Chintan Pharma Stock Screener | Share Price & Fundamental Analysis
TATVA
Specialty Chemicals
Share Price NSE
₹1145.40
▲
19.70 (1.75%)
Share Price BSE
₹1147.00
▲
14.20 (1.25%)
Track Tatva Chintan Pharma share price live with TickJournal's free stock screener.
Analyze Tatva Chintan Pharma share price history trends and compare 52-week high low
levels.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Tatva Chintan Pharma Market Cap
₹2,619.91 Cr.
TATVA P/E Ratio (TTM)
79.52
Tatva Chintan Pharma P/B Ratio
3.45
EPS (TTM)
₹2.44
Dividend Yield
0.09%
Debt to Equity
0.03
TATVA 52 Week High
₹1588.70
Tatva Chintan Pharma 52 Week Low
₹649.30
Operating Margin
19.00%
Profit Margin
11.28%
TATVA Revenue (TTM)
₹133.00
EBITDA
₹27.00
Net Income
₹15.00
Total Assets
₹836.00
Total Equity
₹739.00
Tatva Chintan Pharma Share Price History - Stock Screener Chart
Screen TATVA historical share price movements with interactive charts. Analyze price trends and patterns.
Tatva Chintan Pharma Company Profile - Fundamental Screener
Screen Tatva Chintan Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for TATVA shares.
Sector
Chemicals
Industry
Specialty Chemicals
Sub-Sector
Specialty Chemicals
Segment
E
ISIN
INE0GK401011
Tatva Chintan Pharma Balance Sheet Screener
Screen TATVA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Total Assets | 836 | 819 | 759 | 658 | 315 | 249 | 188 | 0 |
| Current Assets | 265 | 298 | 312 | 436 | 184 | 133 | 114 | 0 |
| Fixed Assets | 526 | 427 | 196 | 160 | 120 | 111 | 67 | 0 |
| Liabilities | ||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 1 | 2 | 5 | 14 | 31 | 44 | 35 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||
| Total Equity | 739 | 737 | 515 | 473 | 166 | 118 | 80 | 0 |
| Share Capital | 23 | 23 | 22 | 22 | 20 | 8 | 8 | 0 |
| Reserves & Surplus | 715 | 714 | 493 | 451 | 146 | 110 | 72 | 0 |
Tatva Chintan Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Tatva Chintan Pharma income statement and profit fundamentals.
Analyze TATVA quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Tatva Chintan Pharma share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 133 | 125 | 118 | 109 | 86 | 84 | 107 | 103 | 85 | 97 | 115 | 125 | 122 | 92 | 90 |
| Expenses | 106 | 101 | 100 | 99 | 79 | 78 | 93 | 83 | 73 | 76 | 93 | 112 | 103 | 79 | 73 |
| EBITDA | 27 | 23 | 19 | 10 | 7 | 6 | 14 | 20 | 12 | 21 | 22 | 14 | 19 | 13 | 17 |
| Operating Profit % | 19.00% | 18.00% | 15.00% | 8.00% | 8.00% | 7.00% | 12.00% | 16.00% | 13.00% | 21.00% | 19.00% | 10.00% | 15.00% | 12.00% | 17.00% |
| Depreciation | 9 | 9 | 9 | 7 | 7 | 7 | 7 | 6 | 7 | 7 | 6 | 3 | 2 | 2 | 2 |
| Interest | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 2 | 1 | 1 |
| Profit Before Tax | 18 | 14 | 9 | 2 | 0 | -1 | 7 | 14 | 5 | 11 | 13 | 8 | 14 | 9 | 14 |
| Tax | 3 | 4 | 3 | 1 | 0 | 0 | 2 | 4 | 2 | 3 | 4 | -9 | 3 | 2 | 4 |
| Net Profit | 15 | 10 | 7 | 1 | 0 | -1 | 5 | 10 | 4 | 8 | 10 | 17 | 12 | 7 | 10 |
| EPS | 6.49 | 4.24 | 2.84 | 0.44 | 0.06 | -0.29 | 2.23 | 4.11 | 1.48 | 3.43 | 4.29 | 7.65 | 5.24 | 3.21 | 4.42 |
Tatva Chintan Pharma Cash Flow Screener - Liquidity Fundamentals
Screen TATVA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | 25 | 98 | 28 | 20 | 20 | 25 | 7 | 13 |
| Investing Activities | -65 | -121 | -101 | -197 | -21 | -40 | -17 | -30 |
| Financing Activities | 17 | 31 | 38 | 235 | -5 | 10 | 17 | 7 |
| Net Cash Flow | -24 | 8 | -36 | 59 | -6 | -5 | 8 | -10 |
Tatva Chintan Pharma Shareholding Pattern Screener
See Tatva Chintan Pharma shareholding pattern with promoter, FII, and DII holdings.
Check Tatva Chintan Pharma promoter holding and ownership changes for TATVA on TickJournal.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% |
| FII Holding | 4.17% | 3.39% | 3.26% | 3.30% | 3.36% | 3.33% | 3.37% | 3.65% |
| DII Holding | 3.33% | 3.86% | 5.11% | 5.46% | 6.34% | 6.82% | 10.63% | 12.84% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 17.91% | 18.29% | 17.47% | 16.92% | 16.33% | 15.95% | 12.44% | 10.49% |
| Other Holding | 2.57% | 2.44% | 2.14% | 2.30% | 1.95% | 1.87% | 1.54% | 1.00% |
| Shareholder Count | 68,657 | 73,331 | 76,792 | 78,393 | 79,009 | 79,623 | 73,912 | 73,730 |
Tatva Chintan Pharma Share Dividend Screener - Share Yield Analysis
Check Tatva Chintan Pharma dividend history with payout and yield data.
View Tatva Chintan Pharma dividend details including ex-dates and amounts for TATVA stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹1.00 | 0.10% |
| 2024-March | ₹2.00 | 0.30% |
| 2023-March | ₹2.00 | 0.19% |
| 2022-March | ₹2.00 | 0.12% |
| 2021-March | ₹5.00 | 0.22% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Tatva Chintan Pharma Stock Index Membership
See which indices include Tatva Chintan Pharma stock.
Check TATVA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX CARBON
BSE INDEX SMLCAP
Tatva Chintan Pharma Market Events Screener - Corporate Actions
Get Tatva Chintan Pharma corporate actions including splits, bonuses, and buybacks.
Check Tatva Chintan Pharma stock events that may affect TATVA share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 1.00 /share | 42.95% | ||
| Dividend | ₹ 2.00 /share | -10.87% | ||
| Dividend | ₹ 2.00 /share | -20.78% | ||
| Annual General Meeting | NA | -2.87% | ||
| Dividend | ₹ 2.00 /share | 0.06% | ||
| Annual General Meeting | NA | -2.06% | ||
| 2026-01-21 | 2026-01-21 | Quarterly Result Announcement | NA | 8.22% |
| 2025-10-31 | 2025-10-31 | Quarterly Result Announcement | NA | 5.47% |
| 2025-07-24 | 2025-07-24 | Quarterly Result Announcement | NA | 5.55% |
| 2025-05-02 | 2025-05-02 | Quarterly Result Announcement | NA | -7.28% |
| 2025-01-28 | 2025-01-28 | Quarterly Result Announcement | NA | -3.45% |
| 2024-10-25 | 2024-10-25 | Quarterly Result Announcement | NA | -5.26% |
Tatva Chintan Pharma Competitors Screener - Peer Comparison
Screen TATVA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Pidilite Industries | 130,244 | 55.96 | 13,388 | 6.91% | 2,096 | 35.70 |
| SRF | 70,742 | 40.24 | 14,826 | 12.13% | 1,251 | 42.38 |
| Gujarat Fluorochemicals | 35,118 | 53.78 | 4,853 | 10.61% | 546 | 48.86 |
| Navin Fluorine International | 30,048 | 55.24 | 2,393 | 12.83% | 289 | 41.36 |
| Himadri Speciality Chemical | 22,523 | 32.18 | 4,664 | 10.33% | 555 | 47.68 |
| Deepak Nitrite | 18,768 | 35.24 | 8,366 | 7.84% | 697 | 42.30 |
| Atul | 18,213 | 30.46 | 5,692 | 18.99% | 499 | 49.36 |
| Aether Industries | 14,554 | 68.00 | 880 | 38.11% | 158 | 54.57 |
| Aarti Industries | 14,489 | 39.20 | 7,285 | 14.16% | 331 | 45.77 |
| Anupam Rasayan | 14,307 | 62.84 | 1,449 | -3.77% | 160 | 51.59 |
Tatva Chintan Pharma Company Announcements - News Screener
Screen TATVA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-03-24 | Closure of Trading Window | - |
| 2026-03-19 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-03-14 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-03-14 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-03-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-25 | Copy Of Report Filed With SEBI Under Regulation 10(7) Of SEBI (Substantial Acquisition Of Shares And Takeover) Regulations 2011. | - |
| 2026-02-25 | Disclosures under Reg. 10(7) of SEBI (SAST) Regulations 2011 | - |
| 2026-02-18 | Announcement under Regulation 30 (LODR)-Acquisition | - |
| 2026-02-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-09 | Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011 | - |
| 2026-02-09 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-02-09 | Disclosures under Reg. 29(1) & 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-02-09 | Filing Of Report Under Regulation 7(2) Of The Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations 2015 As Amended (SEBI Insider Trading Regulations) | - |
| 2026-01-29 | Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations 2011 | - |
| 2026-01-24 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-01-22 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-01-21 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-01-21 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-01-21 | Board Meeting Outcome for Board Meeting Outcome For Outcome Of The Board Meeting Held On 21.01.2026 | - |
| 2026-01-21 | Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine Months Ended On 31 December 2025 | - |